ST. PAUL, Minn.--(BUSINESS WIRE)--3M announced today it has acquired certain assets of Zargis Medical
Corp., maker of the only FDA-approved diagnostic software to classify
suspected systolic and diastolic heart murmurs. Terms of the transaction
were not disclosed.
This acquisition builds on the existing global marketing and
distribution alliance between 3M and Zargis Medical. The combination of
electronic stethoscopes and telemedicine/diagnostic software enables new
and innovative healthcare practices for auscultation, which refers to
listening to internal sounds of the body with a stethoscope.
Included in the transaction are the TELESTETH online auscultation
software, STETHASSIST software, and heart sound analysis software
(Zargis Cardioscan) products developed by Zargis Medical. TeleSteth, a
tele-auscultation software product, provides a cloud server-based system
allowing live, virtual auscultation in a simple, flexible manner using
internet connectivity. TeleSteth also can be used in conjunction with
StethAssist, which adds recording capability and visualization using a
phonocardiogram. These additions to 3M’s LITTMANN Scope to Scope product
line offer tremendous flexibility to healthcare providers.
“Together, Zargis Medical’s diagnostic software used in combination with
the 3M Littmann Stethoscope Model 3200, helps improve patient outcomes
and reduce overall health care costs,” said Ingrid Blair, vice
president, Patient Assessment, 3M Infection Prevention Division.
3M is a trusted leader in auscultation technology. The Littmann Model
3200 features ambient noise reduction technology, which eliminates
approximately 85 percent of distracting background noises without
filtering out critical body sounds, sound amplification up to 24 times
louder than a Littmann cardiology grade stethoscope, frictional noise
reduction technology that reduces handling sounds from the chestpiece,
and extended sound range frequency.
About Zargis Medical Corp.
Zargis is a global medical device
company focused on improving health outcomes and cost-effectiveness
through auscultation software and products. Zargis is majority-owned by
Speedus Corp., and both 3M Company and Siemens Corporate Research, a
division of Siemens AG (NYSE: SI), hold equity positions. For additional
information visit the following Web sites: www.zargis.com
About 3M Health Care
3M Health Care, one of 3M’s six major
business segments, provides world-class innovative products and services
to help healthcare professionals improve the practice, delivery and
outcome of patient care in medical, oral care, drug delivery, food
safety and health information markets. Learn more at www.3M.com/healthcare
TELESTETH, STETHASSIST and LITTMANN are trademarks of 3M.